Compare moats

The FY2025 10-K (fiscal year ended August 29, 2025) documents design-in niches but no durable excess return. In favour: the Competition section says some large rivals 'tend to have limited customization and service capabilities and are generally focused on higher-volume memory, storage, or compute products that are manufactured to industry-standard specifications'. It says the company's 'close collaboration with customers, customer-specific designs, long-lifecycle solutions, superior products and proprietary supply chain services create significant customer loyalty that may provide an advantage when competing against large international companies'. Against: the same filing says many competitors have 'substantially greater financial, technical, marketing, distribution and other resources' and 'lower cost structures'. Sales are made 'primarily pursuant to customer purchase orders and are not based on long-term supply agreements', and 'customers are not obligated to purchase our products even if we achieve a design win'. Large customers 'have exerted' pressure for price concessions, and the ten largest were 66% of fiscal 2025 net sales. GAAP operating income was 0.6%, 1.6% and 4.2% of net sales in fiscal 2023, 2024 and 2025, and fiscal 2024 had a net loss from continuing operations of $41.8 million. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) adds that Advanced Computing nine-month sales fell 20.6%, reflecting 'both the ongoing Penguin Edge wind down and hyperscale hardware sales in 2025 that did not recur in 2026'. The filing's own advantage claim is hedged ('may provide an advantage'): design-in niches exist, but the 10-K shows no durable excess return.

source: sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

source: sec.gov

The strongest candidate moat source in the 10-K is design-in and qualification, a switching-cost argument, and the filing limits it too far to count. The risk factors say 'Our products are often incorporated into customers' systems at the design stage', and many specialty products 'are specifically designed for our OEM customers' systems or products'. But qualification is 'both product-specific and platform-specific', so a design win covers one platform. The filing notes that customers 'sometimes require us to re-qualify our products' for new platforms, which 'can be time-consuming and cause reductions in our net sales', so each new platform reopens the socket. It also says 'customers are not obligated to purchase our products even if we achieve a design win', and warns that OEMs designing in 'standardized or commodity components' could reduce demand for its 'higher priced specialized or customized solutions'. Scale is ruled out because the filing says many competitors have lower cost structures. Patents are ruled out as a durable source. The company holds about 1,650 of them and calls intellectual property 'an important aspect of our business', but it says its patents 'do not cover all of our technologies' and that competitors 'may design around our patented technologies'. It also says some products are 'built around mature industry standards and have less patent protection', so 'we cannot prevent our competitors from reverse-engineering and duplicating those products'.

source: sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

source: sec.gov

The 10-K claims no share figure or rank in any segment. It says 'Our businesses compete with numerous global and local companies'. Its HPC and AI business 'competes primarily with global manufacturers of HPC and AI products and services'. For fault-tolerant solutions it says 'we primarily compete with manufacturers of enterprise servers and industrial computers'. Its memory business competes 'against memory module providers and, to a lesser extent, large semiconductor manufacturers'. The risk factors warn that larger competitors 'may be able to respond better to new or emerging technologies, such as generative AI'. Against that, the company's stated edge is customization and service, where it says some large rivals 'tend to have limited customization and service capabilities'. Its leadership language is self-description without share figures: Cree LED 'has been a leader in LED lighting technology', Stratus Technologies is 'a global leader in simplified, protected and autonomous computing platforms and services', and the memory business is 'a primary supplier of longer-lifecycle solutions to OEM customers'. A specialist that claims no rank and faces many larger, lower-cost rivals, while neither leading nor clearly trailing in its niches, is parity.

source: sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

source: sec.gov

The FY2025 10-K describes price as set by customers and the market. It says its large customers 'are able to exert, have exerted and we expect will continue to exert, pressure on us to make concessions on price and on terms and conditions'. It says 'The markets for our Integrated Memory products have historically been characterized by declines in average selling prices', and that 'Competitive pressure has led in the past and may continue to lead to intensified price competition resulting in lower net sales and lower profit margins'. Gross margin held in a narrow band: 28.8% in fiscal 2023, 29.1% in fiscal 2024 and 28.8% in fiscal 2025. The filing attributes each move to mix, for example higher-margin Advanced Computing service revenue in 2024, not to pricing. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) reports gross margin of 27.8% versus 29.3% a year earlier (27.7% versus 28.9% for nine months), which it attributes to the Penguin Edge wind-down and sales mix. Third-quarter Integrated Memory sales rose 111.4% (75.6% for nine months) as 'accelerating AI-driven demand drove favorable pricing and increased volume', and the 10-Q says that business has 'gross margins which are lower than the Company average'.

source: sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

source: sec.gov

Downstream integrator. Per the 10-K it buys memory from Samsung, Micron, SK hynix and Kioxia and processors from Intel and AMD, and turns them into specialty memory modules and managed AI/HPC clusters for OEM, enterprise, government and cloud customers.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

• AI and HPC infrastructure (OriginAI, ICE ClusterWare) Unknown · Low source: sec.gov
• Cree LED chips and components (XLamp, J Series, high-brightness SMD) Unknown · Low source: sec.gov
• SMART Modular specialty memory and storage (DRAM modules, Zefr, CXL, flash/SSD) Niche · Moderate source: sec.gov
• Stratus fault-tolerant computing (ztC Endurance, ftServer, ztC Edge, everRun) Niche · Low source: sec.gov

• Intismeran autogene (mRNA-4157) Unknown · Moderate source: sec.gov
• Spikevax Top 3 · Moderate source: sec.gov
• mNEXSPIKE Top 3 · Moderate source: sec.gov
• mRESVIA Challenger · Moderate source: sec.gov
• mRNA-1010 seasonal influenza vaccine Unknown · Moderate source: sec.gov

Editorial prior, not backtested.

see exactly how it voted →

Editorial prior, not backtested.

see exactly how it voted →